Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Ovid Therapeutics Inc.NASDAQ: OVID
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $0, compared with $130K a year earlier. Trailing-twelve-month revenue was $7.12M. Over 3 fiscal years it compounded at +69.0% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $805K (-88.9%) for the fiscal year ending Dec 2026, a slowdown from the +1181.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $0-100.0% QoQ
- Last fiscal yearDec 2025
- $7.25M+1181.3% YoY
- LTMMar 2026
- $7.12M+1199.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -100.0% | -99.7% | +0.3 pp |
| 1 year | +1181.3% | -88.9% | -1270.2 pp |
| 3-year CAGR | +69.0% | +28.5% | -40.5 pp |
| 5-year CAGR | +52.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 7.25M USD
- Year-over-year change
- +1181.3%
- 4-year CAGR
- -56.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.25M | +1181.3% |
| FY2024 | 2024-12-31 | 566K | +44.4% |
| FY2023 | 2023-12-31 | 392K | -73.9% |
| FY2022 | 2022-12-31 | 1.5M | -99.3% |
| FY2021 | 2021-12-31 | 208.38M | — |
Revenue vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 revenue of $7.12M is the 7th highest of the 11 companies compared; the peer median is $23.31M.
- Its year-over-year change of +1199.6% is the highest of 8, against a peer median of -32.3%.
- Over three fiscal years its annual growth of +69.0% compares with a peer median of +60.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $669.43M | +13.3% | +22.8% | |
| LTM Mar 2026 | $79.76M | +131.1% | +72.3% | |
| LTM Mar 2026 | $71.8M | -31.6% | +127.1% | |
| LTM Mar 2026 | $36.49M | -45.5% | -0.4% | |
| LTM Mar 2026 | $32.08M | -83.2% | +145.9% | |
| LTM Mar 2026 | $14.54M | — | +60.3% | |
| LTM Mar 2026 | $7.12M | +1199.6% | +69.0% | |
| LTM Jun 2026 | $5.49M | -32.3% | +57.5% | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | — | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding OVID) | $23.31M | -32.3% | +60.3% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| Weighted Avg Shares | 67.48M | 70.43M | 70.58M | 70.91M | 73.74M |
| Weighted Avg Shares (Diluted) | 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.